Youtube
GLAND

Gland Pharma Ltd.

₹3071.9

Score

40

Technically Neutral

Advice

Gland Pharma Price Change Analysis

Gland Pharma Key Statistics
  • P/E Ratio

    51.1

  • PEG Ratio

    1.9

  • Market Cap Cr

    50556.3

  • Price to Book Ratio

    400.8

  • EPS

    60.6

  • Dividend

    0 ()

  • Relative Strength Index

    47.51

  • Money Flow Index

    30.73

  • MACD Signal

    -63.26

  • Average True Range

    116.51

Investment Ratings

  • Master Rating:

EPS Strength

Price Strength

Buyer Demand

Group Rank

Result Highlights

Gland Pharma Synopsis

NSE-Medical-Generic Drugs

Gland Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 3462.88 Cr. and Equity Capital is Rs. 16.36 Cr. for the Year ended 31/03/2021. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.
  • Market Cap

    50,540.77

  • Sales

    4,400.71

  • Shares in Float

    6.91

  • No of Funds

    230

  • Yield

  • Book Value

    8.59

  • U/D Vol Ratio

    0.8

  • LTDebt/Equity

    0

  • Alpha

    -0.02

  • Beta

    0.51

Gland Pharma Ownership
Gland Pharma Management

Gland Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eps And Sales Estimates

Gland Pharma Financials

Gland Pharma Technicals

EMA & SMA

CURRENT PRICE

EMA

Gland Pharma Resistance and Support

Gland Pharma Delivery and Volume

Gland Pharma Price Change Analysis

Corporate Action

MF Shareholding

Similar Stocks

Videos

About Company

News

FAQs

Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.

The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.

Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

The ROE of Gland Pharma Limited is 16% is which good.

Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.

Gland Pharma share price is

Open Demat Account